Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal Article (Journal Article;Review)

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.

Full Text

Duke Authors

Cited Authors

  • Thompson, JA; Schneider, BJ; Brahmer, J; Achufusi, A; Armand, P; Berkenstock, MK; Bhatia, S; Budde, LE; Chokshi, S; Davies, M; Elshoury, A; Gesthalter, Y; Hegde, A; Jain, M; Kaffenberger, BH; Lechner, MG; Li, T; Marr, A; McGettigan, S; McPherson, J; Medina, T; Mohindra, NA; Olszanski, AJ; Oluwole, O; Patel, SP; Patil, P; Reddy, S; Ryder, M; Santomasso, B; Shofer, S; Sosman, JA; Wang, Y; Zaha, VG; Lyons, M; Dwyer, M; Hang, L

Published Date

  • April 2022

Published In

Volume / Issue

  • 20 / 4

Start / End Page

  • 387 - 405

PubMed ID

  • 35390769

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2022.0020

Language

  • eng

Conference Location

  • United States